RXI Pharma (RXII) Misses Q1 EPS by 3c

RXI Pharma (NASDAQ: RXII) reported Q1 EPS of ($0.13), $0.03 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $34 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on RXI Pharma (RXII) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c